<id>25642394</id><source>MED</source><pmid>25642394</pmid><pmcid>PMC4309878</pmcid><DOI>10.1002/brb3.312</DOI><title>The effect of multidisciplinary rehabilitation on brain structure and cognition in Huntington's disease: an exploratory study.</title><authorString>Cruickshank TM, Thompson JA, Domínguez D JF, Reyes AP, Bynevelt M, Georgiou-Karistianis N, Barker RA, Ziman MR.</authorString><authorList><author><fullName>Cruickshank TM</fullName><firstName>Travis M</firstName><lastName>Cruickshank</lastName><initials>TM</initials><affiliation>School of Medical Sciences Edith Cowan University Perth Western Australia Australia.</affiliation></author><author><fullName>Thompson JA</fullName><firstName>Jennifer A</firstName><lastName>Thompson</lastName><initials>JA</initials><affiliation>School of Medical Sciences Edith Cowan University Perth Western Australia Australia.</affiliation></author><author><fullName>Domínguez D JF</fullName><firstName>Juan F</firstName><lastName>Domínguez D</lastName><initials>JF</initials><affiliation>School of Psychological Sciences Monash University Melbourne Victoria Australia.</affiliation></author><author><fullName>Reyes AP</fullName><firstName>Alvaro P</firstName><lastName>Reyes</lastName><initials>AP</initials><affiliation>School of Medical Sciences Edith Cowan University Perth Western Australia Australia.</affiliation></author><author><fullName>Bynevelt M</fullName><firstName>Mike</firstName><lastName>Bynevelt</lastName><initials>M</initials><affiliation>Department of Surgery UWA and Neurological Intervention and Imaging Service of Western Australia Perth Western Australia Australia.</affiliation></author><author><fullName>Georgiou-Karistianis N</fullName><firstName>Nellie</firstName><lastName>Georgiou-Karistianis</lastName><initials>N</initials><affiliation>School of Psychological Sciences Monash University Melbourne Victoria Australia.</affiliation></author><author><fullName>Barker RA</fullName><firstName>Roger A</firstName><lastName>Barker</lastName><initials>RA</initials><affiliation>John van Geest Centre for Brain Repair Cambridge U.K.</affiliation></author><author><fullName>Ziman MR</fullName><firstName>Mel R</firstName><lastName>Ziman</lastName><initials>MR</initials><affiliation>School of Medical Sciences Edith Cowan University Perth Western Australia Australia ; School of Pathology and Laboratory Medicine University of Western Australia Perth Western Australia Australia.</affiliation></author></authorList><journalInfo><journalIssueId>2248666</journalIssueId><dateOfPublication>2015 Jan</dateOfPublication><monthOfPublication>1</monthOfPublication><yearOfPublication>2015</yearOfPublication><journal><title>Brain and behavior</title><ISOAbbreviation>Brain Behav</ISOAbbreviation><medlineAbbreviation>Brain Behav</medlineAbbreviation><NLMid>101570837</NLMid><ESSN>2162-3279</ESSN></journal></journalInfo><pageInfo>e00312</pageInfo><abstractText>OBJECTIVE: This randomised, double-blind, 12-week study compared efficacy and tolerability of flexible-dose treatment with vortioxetine(10-20 mg/day) versus agomelatine (25-50 mg/day) in major depressive disorder patients with inadequate response to selective serotonin reuptake inhibitor (SSRI)/serotonin-noradrenaline reuptake inhibitor (SNRI) monotherapy. METHODS: Patients were switched directly from SSRI/SNRI to vortioxetine or agomelatine. Primary endpoint was change from baseline to week 8 in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score analysed by mixed model for repeated measurements, using a noninferiority test followed by a superiority test. Secondary endpoints included response and remission rates, anxiety symptoms(Hamilton Anxiety Rating Scale), Clinical Global Impression, overall functioning (Sheehan Disability Scale), health-related quality of life(EuroQol 5 Dimensions), productivity (work limitation questionnaire) and family functioning (Depression and Family Functioning Scale). RESULTS: Primary endpoint noninferiority was established and vortioxetine (n = 252) was superior to agomelatine (n = 241) by 2.2 MADRS points (p&lt;0.01). Vortioxetine was also significantly superior in response and remission rates at weeks 8 and 12; MADRS, Hamilton Anxiety Rating Scale, Clinical Global Impression, Sheehan Disability Scale and EuroQol 5 Dimensions scores at week 4 onwards; work limitation questionnaire at week 8 and Depression and Family Functioning Scale at weeks 8 and 12. Fewer patients withdrew because of adverse events with vortioxetine (5.9% vs 9.5%). Adverse events (incidence ?5%) were nausea, headache, dizziness and somnolence. CONCLUSIONS: Vortioxetine was noninferior and significantly superior to agomelatine in major depressive disorder patients with previous inadequate response to a single course of SSRI/SNRI monotherapy. Vortioxetine was safe and well tolerated.</abstractText><affiliation>School of Medical Sciences Edith Cowan University Perth Western Australia Australia.</affiliation><language>eng</language><pubModel>Print-Electronic</pubModel><pubTypeList><pubType>Journal Article</pubType></pubTypeList><keywordList><keyword>Cognition</keyword><keyword>Rehabilitation</keyword><keyword>Neuropathology</keyword><keyword>Huntington's disease</keyword><keyword>Executive Function</keyword></keywordList><fullTextUrlList><fullTextUrl><availability>Subscription required</availability><availabilityCode>S</availabilityCode><documentStyle>doi</documentStyle><site>DOI</site><url>http://dx.doi.org/10.1002/brb3.312</url></fullTextUrl><fullTextUrl><availability>Open access</availability><availabilityCode>OA</availabilityCode><documentStyle>html</documentStyle><site>Europe_PMC</site><url>http://europepmc.org/articles/PMC4309878</url></fullTextUrl><fullTextUrl><availability>Open access</availability><availabilityCode>OA</availabilityCode><documentStyle>pdf</documentStyle><site>Europe_PMC</site><url>http://europepmc.org/articles/PMC4309878?pdf=render</url></fullTextUrl></fullTextUrlList><isOpenAccess>Y</isOpenAccess><inEPMC>Y</inEPMC><inPMC>N</inPMC><citedByCount>0</citedByCount><hasReferences>Y</hasReferences><hasTextMinedTerms>Y</hasTextMinedTerms><hasDbCrossReferences>N</hasDbCrossReferences><hasLabsLinks>N</hasLabsLinks><hasTMAccessionNumbers>N</hasTMAccessionNumbers><dateOfCreation>2015-02-02T00:00:00Z</dateOfCreation><dateOfRevision>2015-02-04T00:00:00Z</dateOfRevision><luceneScore>638.58093</luceneScore></result>
